The American Gastroenterological Association, American College of Gastroenterology and Crohn’s & Colitis Foundation have partnered with Pfizer to offer more than $1 million for research to promote health maintenance and address vaccine use in patients with inflammatory bowel disease, according to a press release.
“Applicants were encouraged to design programs or initiatives that explore or address gaps in vaccine utilization and/or communication amongst providers related to the [request for proposal] topic,” Francis A. Farraye, MD, MSc, FACG, AGAF, director of the Inflammatory Bowel Disease Center at Boston Medical Center and chair of the steering committee for the partnership between ACG, AGA, and the Crohn’s & Colitis Foundation, said in the release. “These projects were selected for their potential to overcome barriers by helping to identify and establish best practices around improving vaccine utilization and preventive health maintenance for patients with IBD. The selected projects also have the potential to be easily replicated, broadly disseminated, and widely adopted within the IBD community.”
This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2019 Healio All Rights Reserved.